Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine Inc.

An announcement from Editas Medicine ( ($EDIT) ) is now available. At its June 17, 2026 annual meeting, Editas Medicine stockholders elected Bernad...

Editas Medicine Shareholders Back Board, Pay and Auditor

An announcement from Editas Medicine ( ($EDIT) ) is now available. On May 26, 2026, Editas Medicine, Inc. priced an underwritten public offering of...

Market Cap	$221.84M	P/E Ratio	N/A
52W High	$4.54	52W Low	$1.66
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	17.5%	52W Position	38.2%
Overall Score	46	Value Score	40
Quality Score	39	Technical Score	60

EPS Current Est	$-1.03	EPS Next Est	$-1
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EDIT	$2.76	-1.43%	1.99M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EDIT	$2.76	-1.4%	1.99M
3
4
5
6

EDIT

EDIT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Editas Medicine Inc. Data in Excel

Get Editas Medicine Inc. Data in Excel